Cynata has manufacturing solution for new covd treatments, page-23

CEO Ross Macdonald confirmed talks are ongoing but told us “We cannot disclose the names of any of the companies or other parties with which we are in conversations.”

Tweet by Ross just out....

https://bioprocessintl.com/bioprocess-insider/therapeutic-class/growing-interest-in-stem-cells-for-covid-19-ailments-says-cynata/

Several of Cynata’s therapies are already in preclinical development for COVID-19 related conditions.

For example, the firm says Cymerus MSCs were able to increase blood oxygen levels and lung compliance while reducing alveolar neutrophil infiltration in a preclinical model of severe pneumonia-induced sepsis.

Likewise, the candidate therapies helped protect mice against cytokine release syndrome, which is another COVID-19 complication.

In addition, Cynata recently published preclinical data that support the use of Cymerus MSCs for a range of pulmonary diseases, including asthma and idiopathic pulmonary fibrosis.

The firm is also testing whether its therapies can be used to treat acute respiratory distress syndrome in collaboration with the Critical Care Research Group at Prince Charles Hospital in Brisbane, Australia.